Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ritter Pharmaceuticals Inc    RTTR

RITTER PHARMACEUTICALS INC

(RTTR)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

RITTER PHARMACEUTICALS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:15pm EDT

Item 2.02. Results of Operation and Financial Condition

On August 14, 2019, Ritter Pharmaceuticals, Inc. (the "Company"), issued a press release announcing the financial results for the three and six months ended June 30, 2019, entitled "Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update" (the "Press Release"). A copy of the Press Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of Section 18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section 18. Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references in such filings.

Item 9.01. Financial Statements and Exhibits



(d) Exhibits



Exhibit No.   Description

99.1            Press Release dated August 14, 2019, entitled "Ritter
              Pharmaceuticals Reports Financial Results for the Three and Six
              Months Ended June 30, 2019 and Provides a Corporate Update"











Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



  RITTER PHARMACEUTICALS, INC.

  By:    /s/ Andrew J. RitterName:  Andrew J. Ritter
  Title: Chief Executive Officer



Date: August 14, 2019

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RITTER PHARMACEUTICALS INC
08/14RITTER PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
08/14RITTER PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fina..
AQ
08/14Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months..
GL
08/13Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo,..
GL
08/08Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Re..
GL
07/31Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight R..
GL
07/24RITTER PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Unregis..
AQ
07/12RITTER PHARMACEUTICALS : Regains Compliance with Nasdaq's Minimum Bid Price Requ..
AQ
07/11Ritter Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price Req..
GL
07/11RITTER PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (fo..
AQ
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -15,3 M
Net income 2019 -15,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -0,74x
P/E ratio 2020 -1,68x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 8,63 M
Chart RITTER PHARMACEUTICALS INC
Duration : Period :
Ritter Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RITTER PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 6,50  $
Last Close Price 0,92  $
Spread / Highest target 658%
Spread / Average Target 604%
Spread / Lowest Target 550%
EPS Revisions
Managers
NameTitle
Andrew J. Ritter President, CEO, Secretary & Director
Ira E. Ritter Executive Chairman & Chief Strategic Officer
John W. Beck Chief Financial Officer
Diane J. Plotkin Vice President-Clinical Development
Noah J. Doyle Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RITTER PHARMACEUTICALS INC53.90%8
GILEAD SCIENCES0.94%79 622
VERTEX PHARMACEUTICALS11.60%46 554
REGENERON PHARMACEUTICALS-20.52%32 073
GENMAB26.56%13 013
SAREPTA THERAPEUTICS INC14.50%9 067